<DOC>
	<DOCNO>NCT00703846</DOCNO>
	<brief_summary>Extina ( ketoconazole ) Foam , 2 % approve marketing United States ( US ) June 2007 . Extina foam indicate topical treatment seborrheic dermatitis immunocompetent patient 12 year age old . The approved dose regimen twice daily 4 week . The treatment recurrent seborrheic dermatitis demand topical preparation safe short-term chronic application . This study conduct order obtain long-term safety data use Extina ( ketoconazole ) Foam , 2 % treatment seborrheic dermatitis .</brief_summary>
	<brief_title>STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA ( KETOCONAZOLE ) FOAM , 2 %</brief_title>
	<detailed_description>This open-label , multicenter , single-group study ass long-term safety twice daily treatment Extina ( ketoconazole ) Foam , 2 % subject seborrheic dermatitis . The study subject must seborrheic dermatitis Investigator 's Static Global Assessment ( ISGA ) 2 , 3 , 4 baseline . In addition , subject must discrete , evaluable target area least 0.5 cm2 , score 2 , 3 , 4 erythema scaling . All subject apply Extina ( ketoconazole ) Foam , 2 % topically twice day ( morning evening ) seborrheic dermatitis lesion face , scalp , ear , neck , chest . Study product apply first sign seborrheic dermatitis flare , twice daily application continue area ( ) clear . All symptom flare treat throughout 12-month study period . Study visit occur baseline ( day 1 ) week 4 , 8 , 16 , 26 , 39 , 52 ( early withdrawal ) . See study flowchart ( section 3 ) assessment perform visit . Primary Objective : To assess long-term safety Extina ( ketoconazole ) Foam , 2 % treatment seborrheic dermatitis .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Seborrheic</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Subjects must fulfill follow condition characteristic order consider study enrollment : 1 . Capable understanding willing provide sign dated write voluntary informed consent protocolspecific procedure perform . For subject age 12 17 year , parent legal guardian must capable understand willing sign inform consent subject must capable understand willing sign adolescent assent . 2 . Male female subject 12 year age old . 3 . Able complete study comply study instruction . 4 . Female subject childbearing potential must negative pregnancy test . Sexually active woman childbearing potential participating study must use medically acceptable form contraception ( include oral contraception , injectable implantable method , intrauterine device ) . Barrier method contraception acceptable . A woman childbearing potential define one biologically capable become pregnant . Abstinence consider appropriate barrier control method . 5 . Seborrheic dermatitis face , scalp , ear , neck , chest ISGA 2 , 3 , 4 baseline 6 . Subjects must discrete , evaluable target area least 0.5 cm2 , score 2 , 3 , 4 erythema scale Seborrheic Dermatitis Grading Scale Subjects follow condition characteristic exclude study enrollment : 1 . Use systemic antifungal agent , corticosteroid immunosuppressive therapy , systemic retinoids within 4 week prior baseline visit . 2 . Use topical antifungal therapy , corticosteroid therapy , calcineurin inhibitor face , scalp , ear , neck , chest within 2 week prior baseline visit . 3 . Use investigational drug within 8 week prior baseline visit , subject schedule receive investigative drug study product period study . 4 . History know suspect intolerance ingredient study product . 5 . Female subject pregnant , try become pregnant , lactate . 6 . Any clinically relevant abnormal vital sign finding physical examination . 7 . A clinically relevant history abuse alcohol drug . 8 . Any major illness within 30 day prior baseline visit . 9 . Subjects clinically significant condition would , opinion investigator , compromise subject 's participation study . 10 . Subjects immunocompromised . 11 . Considered unable unlikely attend necessary visit . 12 . Employees Stiefel Laboratories contract research organization involve study , immediate family member ( partner , offspring , parent , sibling , sibling 's offspring ) employee . 13 . Currently use medication , opinion investigator may affect evaluation study product place subject undue risk . 14 . Only one subject per household may enter study . These inclusion exclusion criterion strictly adhere throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Phase 4</keyword>
	<keyword>Seborrheic</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Dermatitis</keyword>
</DOC>